

Scandion Oncology – Notice convening the Annual General Meeting

The appointed liquidator hereby gives notice of the annual general meeting in:

Scandion Oncology A/S (under frivillig likvidation)
CVR no. 38613391
(the "**Company**")

to be held on Tuesday, June 30, 2026, at 13.00 (CEST), at HortenDahl Advokatpartnerselskab, Philip Heymans Alle 7, 2900 Hellerup, Denmark.

With the following agenda:

1. Election of chairman of the meeting
 - The appointed liquidator proposes that Rune Koster, attorney-at-law, is elected chairman of the meeting
2. Report from the appointed liquidator on the Company's business in the past year
3. Presentation of the audited annual report for approval
 - The appointed liquidator proposes that the audited annual report for 2025 is approved
4. Proposal of notice of discharge to the board of directors and the executive board
 - The appointed liquidator proposes granting discharge to the board of directors and the executive board based on the information in the annual report for the period from January 1, 2025 until their resignation on March 27, 2025.
5. Decision on appropriation of profit or loss as recorded in the approved annual report
 - The appointed liquidator proposes to appropriate the year's result as set out in the annual report.
6. Election of auditor
 - The appointed liquidator proposes to re-elect Deloitte Statsautoriseret Revisionspartnerselskab as the Company's auditor
7. Any other business

Attendance and casting of votes at the general meeting

A shareholder's right to attend the general meeting and to vote on its shares is determined on the basis of the shares held by the shareholder at the date of registration.

The date of registration is June 23, 2026 ("**Date of Registration**").

Only shareholders in the Company as at the Date of Registration have the right to attend the annual general meeting and vote on their shares.

The shares held by each shareholder at the Date of Registration are calculated based on the registration of the number of shares held by the shareholder in the Company's register of shareholders as well as any notification of ownership received by the Company on or before the Date of Registration for the purpose of registration in the Company's register of shareholders, but which as of the Date of Registration had not yet been registered.

Any sale or purchase of shares in the Company taking place after the Date of Registration and until the date of the general meeting will not affect voting rights at the general meeting or any postal votes.

Admission Card, Proxy and Postal Voting

In order to attend the general meeting, a shareholder must request an admission card no later than June 28, 2026, 11.59 p.m. (CEST). The request shall be made to the Company, e-mail: info@scandiononcology.com.

All shareholders are entitled to attend the general meeting by proxy. If a shareholder wishes to attend by proxy, the shareholder will need to request an admission card for the proxy holder as set out above and fill out a written and dated instrument of proxy. The proxy holder must be able to present the admission card and the written and dated instrument of proxy at the general meeting.

Proxies may be submitted in writing by using the written proxy form attached to this notice as schedule 2 and which can also be found on the Company's website www.scandiononcology.com. The Company requests that signed forms are received by the Company by e-mail to: info@scandiononcology.com no later than June 28, 2026 at 11.59 p.m. (CEST). Proxies received after this date cannot be expected to have been received at the general meeting.

A shareholder can also choose to make use of postal vote instead of attending the annual general meeting in person.

Postal votes may be submitted in writing by using the postal vote form attached to this notice as schedule 2 and which also can be found on the Company's website www.scandiononcology.com. A completed and signed form must be received by the Company by e-mail to: info@scandiononcology.com no later than June 28, 2026 at 11.59 p.m. (CEST).

Postal votes received by the Company cannot be cancelled or revoked.

Nominee

To be entitled to participate in the general meeting, shareholders whose shares are registered in the name of a nominee must re-register their shares in their own names in the share register. Such registration must be duly effected in the share register or duly notified to the Company on the Date of Registration, and the shareholders must therefore advise their nominees well in advance of the general meeting.

Please note that a nominee is entitled to participate in the general meeting for the shares registered in the nominee's name. In such case, the nominee is responsible for acting only on the basis of explicit instruction from the actual owner(s) of the shares in question.

June 15, 2026

Appointed Liquidator of Scandion Oncology A/S (under frivillig likvidation)

E-mail: info@scandiononcology.com

Schedules

Schedule 1: Annual report

Schedule 2: Proxy and postal vote form